The Johns Hopkins University

Vermillion Corporation

University of Texas System

Vermilllion, Inc.

Aspira Women's Health Inc.

Ciphergen Biosystems, Inc.

Daniel W Chan

Zhen Zhang

Eric Thomas Fung

Xiao-Ying Meng

Fujun Zhang

Zheng Wang

Robert C Bast

Vladimir Podust

Hui Zhang

Jin Song

Yan Li

Valdimir Podust

Carolyn N White

Jinong Li

Carolyn N Rosenzwelg

Lori J Sokoll

Jing Chen

Yuan Tian

Xiangchun Wang

Danni Li

Donald Munroe

Robert Bast

The present invention provides a protein-based biomarker that is useful in qualifying ovarian cancer status in a patient. In particular, the biomarker of this invention is useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarker can be detected by SELDI mass spectrometry.

Biomarkers for ovarian cancer CTAP3-related proteins

The present invention relates to the field of biomarkers. More specifically, the present invention relates to biomarkers useful in diagnosing aggressive prostate cancer. In one embodiment, a method for identifying patients as having or likely to have aggressive prostate cancer comprises the steps of (a) obtaining a biological sample from the patient; (b) performing an assay on the biological sample to detect fucosylated fucosylated DPP-4, sTIE-2, sVEGFR-1, and FUT8; and (c) identifying the patient as having or likely to have aggressive prostate cancer if there is a statistically significant difference in the levels of fucosylated TIMP-1, fucosylated DPP-4, sTIE-2, sVEGFR-1 and FUT8.

Biomarkers for aggressive prostate cancer

Biomarker for ovarian cancer CTAP3-related proteins

The present invention relates to the field of biomarkers and, more specifically, to biomarkers useful in diagnosing aggressive prostate cancer. In specific embodiments, a method for diagnosing aggressive prostate cancer in a patient comprises (a) measuring the levels of one or more biomarkers in a sample collected from the patient; and (b) comparing the levels of the one or more biomarkers with predefined levels of the same biomarkers that correlate to a patient having aggressive prostate cancer and predefined levels of the same biomarkers that correlate to a patient not having aggressive prostate cancer, wherein a correlation to one of the predefined levels provides the diagnosis. In a specific embodiment, the one or more biomarkers may comprise cathepsin-L (CTSL), periostin, microfibrillar-associated protein 4 (MFAP4), collagen XII, neprilysin, clusterin, neutrophil gelatinase associated lipocalin (NGAL), epithelial cell activating molecule (EpCAM), prostate specific antigen (PSA), membrane metallo-endopeptidase (MME) and asporin (ASPN).

The invention features compositions and methods that are useful for precisely determining the amount of one or more analytes present in a sample. In one aspect, the invention provides a composition for measuring the abundance of one or more target analytes in a sample, where the composition contains a set of detection units for each analyte fixed to a substrate (e.g., a membrane, bead, filter, chip, polymer-based film or glass slide, or other printable surface), where each detection unit contains a discrete amount of a capture agent that specifically binds the target analyte, and the amount of capturing agent varies over the set to form a concentration gradient.

High precision quantitative assay composition and methods of use therefor

The present invention relates to a method of qualifying ovarian cancer status in a subject comprising: (a) measuring at least one biomarker in a sample from the subject and (b) correlating the measurement with ovarian cancer status. The invention further relates to kits for qualifying ovarian cancer status in a subject.

Biomarkers for ovarian cancer

The instant invention provides methods and compositions for the detection of prostate cancer is a subject. In one embodiment, a method of detecting prostate cancer in a subject comprises the steps of (a) detecting the presence of at least one biomarker listed in Table 1 in a serum sample, wherein the presence of the biomarker in the serum sample is indicative of prostate cancer.

Biomarkers for prostate cancer

The present invention provides a protein-based biomarker, Protein C Inhibitor (PCI) that is useful in qualifying prostate cancer status in a patient. In particular, the biomarker of this invention is useful to classify a subject sample as prostate cancer or non-prostate cancer. The biomarker can be detected by SELDI mass spectrometry.

Protein C inhibitor as a biomarker for prostate cancer

The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying breast cancer status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as breast cancer or non-breast cancer. The biomarkers can be detected by SELDI mass spectrometry.

Biomarkers for breast cancer

Use of biomarkers for detecting ovarian cancer

The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status as well as endometrical cancer status in a patient. In particular, it has been found that hepcidin is a biomarker for both ovarian cancer and endometrial cancer and that a panel of biomarkers, including hepcidin, transthyretin and optionally other markers are useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry.

Biomarker for ovarian and endometrial cancer: hepcidin

Growing community of inventors

Clarksville, MD, United States of America

Daniel W Chan